Sibylle Loibl, Chief Executive Officer at the German Breast Group Research Company (GBG Forschungs GmbH), shared a post on LinkedIn:
“Hot from the press: ESMO Open
The PADMA (GBG93) study is the first randomized multicenter trial to demonstrate that palbociclib combined with endocrine therapy (ET) is superior to standard single-agent chemotherapy as first-line treatment for patients with HR-positive/HER2-negative metastatic breast cancer, even in a high-risk population with a clinical indication for chemotherapy.
Key findings
- Time-to-treatment failure (TTF), the primary endpoint, was nearly tripled with palbociclib + ET:
17.2 months vs. 6.1 months with chemotherapy
Corresponding to a 54% reduction in risk. - Progression-free survival (PFS) was also significantly prolonged:
18.7 months vs. 7.8 months
Corresponding to a 55% reduction in risk. - The benefit was consistent across all analyzed subgroups, including patients with AKT pathway alterations or BRCA1/2 mutations.”
Title: First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study
Authors: M. Schmidt, M. Thill, J. Rey, B. Rautenberg, V. Bjelic-Radisic, T. Decker, J. Rom, M. Kögel, K. Lübbe, A. Nacke, S. Seiler, M. Just, V. Müller, R. Buss-Steidle, J. Terhaag, C. Mundhenke, C. Denkert, J. Holtschmidt, S. Loibl
Read the Full Article.
You can also read:
